Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.95
BMY's Cash to Debt is ranked higher than
63% of the 1158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. BMY: 0.95 )
BMY' s 10-Year Cash to Debt Range
Min: 0.36   Max: 2.26
Current: 0.95

0.36
2.26
Equity to Asset 0.44
BMY's Equity to Asset is ranked higher than
56% of the 965 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. BMY: 0.44 )
BMY' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.52
Current: 0.44

0.33
0.52
Interest Coverage 12.76
BMY's Interest Coverage is ranked higher than
55% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 236.52 vs. BMY: 12.76 )
BMY' s 10-Year Interest Coverage Range
Min: 4.67   Max: 50.72
Current: 12.76

4.67
50.72
F-Score: 6
Z-Score: 5.82
M-Score: -2.28
WACC vs ROIC
7.90%
7.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.32
BMY's Operating margin (%) is ranked higher than
86% of the 1107 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.08 vs. BMY: 16.32 )
BMY' s 10-Year Operating margin (%) Range
Min: 10.45   Max: 31.04
Current: 16.32

10.45
31.04
Net-margin (%) 12.62
BMY's Net-margin (%) is ranked higher than
85% of the 1107 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.46 vs. BMY: 12.62 )
BMY' s 10-Year Net-margin (%) Range
Min: 9.19   Max: 56.42
Current: 12.62

9.19
56.42
ROE (%) 13.19
BMY's ROE (%) is ranked higher than
82% of the 1135 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.08 vs. BMY: 13.19 )
BMY' s 10-Year ROE (%) Range
Min: 13.25   Max: 78.36
Current: 13.19

13.25
78.36
ROA (%) 5.80
BMY's ROA (%) is ranked higher than
77% of the 1169 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. BMY: 5.80 )
BMY' s 10-Year ROA (%) Range
Min: 5.54   Max: 35.08
Current: 5.8

5.54
35.08
ROC (Joel Greenblatt) (%) 52.63
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 1164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.30 vs. BMY: 52.63 )
BMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 36.14   Max: 149.91
Current: 52.63

36.14
149.91
Revenue Growth (3Y)(%) -8.40
BMY's Revenue Growth (3Y)(%) is ranked higher than
54% of the 948 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. BMY: -8.40 )
BMY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -8.4   Max: 11.8
Current: -8.4

-8.4
11.8
EBITDA Growth (3Y)(%) -26.60
BMY's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. BMY: -26.60 )
BMY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -26.6   Max: 21.5
Current: -26.6

-26.6
21.5
EPS Growth (3Y)(%) -17.80
BMY's EPS Growth (3Y)(%) is ranked higher than
61% of the 822 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. BMY: -17.80 )
BMY' s 10-Year EPS Growth (3Y)(%) Range
Min: -22.9   Max: 30.7
Current: -17.8

-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BMY Guru Trades in Q2 2014

Joel Greenblatt 89,363 sh (New)
Ken Fisher 49,732 sh (+216.10%)
Paul Tudor Jones 34,712 sh (+112.32%)
Jim Simons 2,459,200 sh (+64.84%)
Vanguard Health Care Fund 36,197,961 sh (+22.96%)
Brian Rogers 6,064,800 sh (+3.41%)
Pioneer Investments 85,646 sh (+0.94%)
Murray Stahl 62,972 sh (+0.48%)
Ronald Muhlenkamp 212,770 sh (+0.36%)
Steven Cohen 3,900 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Ray Dalio Sold Out
Dodge & Cox 78,921 sh (-0.25%)
Bill Frels 293,539 sh (-1.11%)
Mario Gabelli 674,685 sh (-1.76%)
Irving Kahn 27,650 sh (-6.75%)
Jean-Marie Eveillard 14,492 sh (-12.28%)
Jeff Auxier 5,043 sh (-12.78%)
Jeremy Grantham 1,821,771 sh (-56.04%)
» More
Q3 2014

BMY Guru Trades in Q3 2014

Ray Dalio 10,228 sh (New)
Dodge & Cox 90,428 sh (+14.58%)
Vanguard Health Care Fund 38,480,761 sh (+6.31%)
Mario Gabelli 700,255 sh (+3.79%)
Brian Rogers 6,264,800 sh (+3.30%)
Ken Fisher 51,201 sh (+2.95%)
Bill Frels 294,435 sh (+0.31%)
Pioneer Investments 84,994 sh (unchged)
Jeff Auxier 5,043 sh (unchged)
Irving Kahn 27,650 sh (unchged)
Jean-Marie Eveillard 14,492 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Murray Stahl 62,942 sh (-0.05%)
Ronald Muhlenkamp 212,485 sh (-0.13%)
Jeremy Grantham 1,520,723 sh (-16.53%)
Paul Tudor Jones 14,869 sh (-57.16%)
Jim Simons 270,900 sh (-88.98%)
» More
Q4 2014

BMY Guru Trades in Q4 2014

Steven Cohen 246,400 sh (New)
Ruane Cunniff 3,670 sh (New)
Jim Simons 298,500 sh (+10.19%)
Irving Kahn 28,400 sh (+2.71%)
Vanguard Health Care Fund 39,056,361 sh (+1.50%)
Mario Gabelli 709,715 sh (+1.35%)
Dodge & Cox 91,028 sh (+0.66%)
Bill Frels 295,035 sh (+0.20%)
Jeff Auxier 5,043 sh (unchged)
Jean-Marie Eveillard 14,492 sh (unchged)
Brian Rogers 6,264,800 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 212,290 sh (-0.09%)
Murray Stahl 62,817 sh (-0.20%)
Pioneer Investments 84,466 sh (-0.62%)
Ken Fisher 30,739 sh (-39.96%)
Jeremy Grantham 10,762 sh (-99.29%)
» More
Q1 2015

BMY Guru Trades in Q1 2015

Brian Rogers 5,814,800 sh (-7.18%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1110.230.18$2.00 Convertible Preferred Stock

Guru Investment Theses on Bristol-Myers Squibb Company

Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company - Mar 27, 2015

We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company
We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period. Read more...
Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 55.00
BMY's P/E(ttm) is ranked higher than
72% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 64.60 vs. BMY: 55.00 )
BMY' s 10-Year P/E(ttm) Range
Min: 4.05   Max: 58.14
Current: 55

4.05
58.14
Forward P/E 28.17
BMY's Forward P/E is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BMY: 28.17 )
N/A
PE(NRI) 55.70
BMY's PE(NRI) is ranked higher than
75% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.40 vs. BMY: 55.70 )
BMY' s 10-Year PE(NRI) Range
Min: 12.82   Max: 57.93
Current: 55.7

12.82
57.93
P/B 7.30
BMY's P/B is ranked higher than
51% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. BMY: 7.30 )
BMY' s 10-Year P/B Range
Min: 2.46   Max: 7.57
Current: 7.3

2.46
7.57
P/S 6.92
BMY's P/S is ranked lower than
56% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. BMY: 6.92 )
BMY' s 10-Year P/S Range
Min: 1.63   Max: 7.13
Current: 6.92

1.63
7.13
PFCF 41.30
BMY's PFCF is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BMY: 41.30 )
BMY' s 10-Year PFCF Range
Min: 7.44   Max: 141.78
Current: 41.3

7.44
141.78
POCF 35.54
BMY's POCF is ranked higher than
78% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.91 vs. BMY: 35.54 )
BMY' s 10-Year POCF Range
Min: 6.95   Max: 44.77
Current: 35.54

6.95
44.77
EV-to-EBIT 43.06
BMY's EV-to-EBIT is ranked higher than
75% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.18 vs. BMY: 43.06 )
BMY' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 179.4
Current: 43.06

6.6
179.4
Shiller P/E 28.20
BMY's Shiller P/E is ranked higher than
90% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BMY: 28.20 )
BMY' s 10-Year Shiller P/E Range
Min: 10.15   Max: 29.08
Current: 28.2

10.15
29.08
Current Ratio 1.73
BMY's Current Ratio is ranked higher than
64% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. BMY: 1.73 )
BMY' s 10-Year Current Ratio Range
Min: 1.15   Max: 2.21
Current: 1.73

1.15
2.21
Quick Ratio 1.54
BMY's Quick Ratio is ranked higher than
70% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 1.54 )
BMY' s 10-Year Quick Ratio Range
Min: 0.95   Max: 1.99
Current: 1.54

0.95
1.99
Days Inventory 147.49
BMY's Days Inventory is ranked higher than
69% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. BMY: 147.49 )
BMY' s 10-Year Days Inventory Range
Min: 84.37   Max: 204.87
Current: 147.49

84.37
204.87
Days Sales Outstanding 48.27
BMY's Days Sales Outstanding is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. BMY: 48.27 )
BMY' s 10-Year Days Sales Outstanding Range
Min: 37.65   Max: 82.36
Current: 48.27

37.65
82.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.22
BMY's Dividend Yield is ranked higher than
76% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. BMY: 2.22 )
BMY' s 10-Year Dividend Yield Range
Min: 2.14   Max: 7.07
Current: 2.22

2.14
7.07
Dividend Payout 1.21
BMY's Dividend Payout is ranked higher than
84% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BMY: 1.21 )
BMY' s 10-Year Dividend Payout Range
Min: 0.23   Max: 1.38
Current: 1.21

0.23
1.38
Dividend growth (3y) 2.90
BMY's Dividend growth (3y) is ranked higher than
71% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. BMY: 2.90 )
BMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 11.4
Current: 2.9

0
11.4
Yield on cost (5-Year) 2.55
BMY's Yield on cost (5-Year) is ranked higher than
71% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. BMY: 2.55 )
BMY' s 10-Year Yield on cost (5-Year) Range
Min: 2.48   Max: 8.2
Current: 2.55

2.48
8.2
Share Buyback Rate 0.90
BMY's Share Buyback Rate is ranked higher than
92% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. BMY: 0.90 )
BMY' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -0.3
Current: 0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.00
BMY's Price/Tangible Book is ranked lower than
53% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. BMY: 18.00 )
BMY' s 10-Year Price/Tangible Book Range
Min: 6.33   Max: 53.3
Current: 18

6.33
53.3
Price/DCF (Projected) 2.20
BMY's Price/DCF (Projected) is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BMY: 2.20 )
BMY' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 4.14
Current: 2.2

1.13
4.14
Price/Median PS Value 2.60
BMY's Price/Median PS Value is ranked higher than
54% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 2.60 )
BMY' s 10-Year Price/Median PS Value Range
Min: 0.89   Max: 3.25
Current: 2.6

0.89
3.25
Price/Graham Number 6.60
BMY's Price/Graham Number is ranked higher than
67% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.40 vs. BMY: 6.60 )
BMY' s 10-Year Price/Graham Number Range
Min: 1.66   Max: 10.79
Current: 6.6

1.66
10.79
Earnings Yield (Greenblatt) 2.30
BMY's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. BMY: 2.30 )
BMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 15.2
Current: 2.3

0.6
15.2
Forward Rate of Return (Yacktman) -14.28
BMY's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.03 vs. BMY: -14.28 )
BMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.7   Max: 27.5
Current: -14.28

-14.7
27.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BRM.Germany, BMYMP.USA, BMYB34.Brazil, BMY.Mexico, BMY.Argentina, BMY.Switzerland,
Bristol-Myers Squibb Co is a Delaware corporation and was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called 'biologics'. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others. The Company promotes its products to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and competitive. The Company competes with other research-based drug companies, research companies and generic drug manufacturers. The Company is subject to regulation by regional, country, state and local agencies.
» More Articles for BMY

Headlines

Articles On GuruFocus.com
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
Piper Jaffray Sees Potential in uniQure NV (QURE) and Bristol-Myers Squibb (BMY) Collaboration Apr 07 2015 
Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Weekly Insider Sells Highlight: MHK, JAZZ, BMY, ZAYO Mar 23 2015 
Top Pharma Stock Picks For March Mar 13 2015 
Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Abner Herrman's Top Three Holdings Feb 26 2015 


More From Other Websites
Bristol-Myers says hepatitis C drug combination succeeds in study Apr 25 2015
ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver... Apr 25 2015
Final Glance: Pharmaceuticals companies Apr 24 2015
Final Glance: Pharmaceuticals companies Apr 24 2015
Cramer game plan: Countdown to Apple-play it right Apr 24 2015
Midday Glance: Pharmaceuticals companies Apr 24 2015
Midday Glance: Pharmaceuticals companies Apr 24 2015
Early Glance: Pharmaceuticals companies Apr 24 2015
Early Glance: Pharmaceuticals companies Apr 24 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for... Apr 24 2015
7:46 am Bristol-Myers Squibb confirms positive CHMP opinion in the European Union for Opdivo... Apr 24 2015
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog Apr 21 2015
Cardinal Health’s $27M settlement causes rift at Federal Trade Commission Apr 21 2015
Top Analyst Upgrades and Downgrades: GE, IBM, Bristol-Myers, Encana, Halliburton, Rio Tinto,... Apr 21 2015
Morgan Stanley Says 'Buy The Leader In IO,' Upgrades Bristol-Myers To Overweight Apr 21 2015
Bristol-Myers upgraded by Morgan Stanley Apr 21 2015
Bristol-Myers Drug Combination Shows Promise Against Melanoma Apr 20 2015
Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK